SCHEMBL2995429

SCHEMBL2995429

CC(=O)Nc1ccc(-c2cc3cc(CN4CCS(=O)(=O)CC4)cc(NC4CCCC4)c3[nH]2)cc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
ROCK2 O75116 4/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.39
JAK1 P23458 1/20 0.38
BRD4 O60885 1/20 0.37
OPRM1 P35372 1/20 0.36
SLC2A1 P11166 1/20 0.36
PRKCZ Q05513 1/20 0.36
PRKD2 Q9BZL6 1/20 0.36
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3418751 0.93 ALDH1A1 (0.40) ALDH1A1RAB9ANPC1ROCK2KDM4E
SCHEMBL3420155 0.85 ACP1 (0.43) ROCK2PKM
SCHEMBL3418298 0.84 ALDH1A1 (0.39) ALDH1A1RAB9ANPC1ROCK2KDM4E
SCHEMBL25924584 0.84 ALDH1A1 (0.48) ALDH1A1RAB9ANPC1KDM4EMAPT
SCHEMBL3011386 0.83 ALDH1A1 (0.43) ALDH1A1RAB9ANPC1KDM4EMAPT
SCHEMBL16427973 0.83 ALDH1A1 (0.40) ALDH1A1RAB9ANPC1KDM4EMAPT
SCHEMBL3419136 0.83 CSF1R (0.41) ALDH1A1RAB9ANPC1KDM4EMAPT
SCHEMBL16523105 0.81 RAB9A (0.36) ALDH1A1RAB9ANPC1ROCK2KDM4E
SCHEMBL3415489 0.80 VCP (0.40) ALDH1A1KDM4E
SCHEMBL3415437 0.79 VCP (0.40) ALDH1A1RAB9AKDM4EMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213583-A1 ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF MITOIMMUNE THERAPEUTICS INC. (KR) 2025-07-03 US claimed
US-20250082646-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF MITOIMMUNE THERAPEUTICS INC. (KR) 2025-03-13 US claimed
EP-4470541-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF MitoImmune Therapeutics Inc. (KR) 2024-12-04 EP claimed
US-20240374646-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME MITOIMMUNE THERAPEUTICS INC. (KR) 2024-11-14 US claimed
WO-2024191106-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF EPILEPSY 주식회사 미토이뮨테라퓨틱스 2024-09-19 WO claimed
US-20240269145-A1 USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS MITOIMMUNE THERAPEUTICS INC. (KR) 2024-08-15 US claimed
EP-4382106-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME MitoImmune Therapeutics Inc. (KR) 2024-06-12 EP claimed
WO-2023182840-A1 ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF 주식회사 미토이뮨테라퓨틱스 2023-09-28 WO claimed
WO-2023146341-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF 주식회사 미토이뮨테라퓨틱스 2023-08-03 WO claimed
WO-2022220517-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME 주식회사 미토이뮨테라퓨틱스 2022-10-20 WO claimed
EP-2178870-B1 INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG CHEMICAL LTD (KR) 2018-09-19 EP claimed
US-20150038500-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2015-02-05 US claimed
US-8436038-B2 Indole and indazole compounds as an inhibitor of cellular necrosis LG LIFE SCIENCES LTD. (KR) 2013-05-07 US claimed
US-20100197673-A1 INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG LIFE SCIENCES LTD (KR) 2010-08-05 US claimed
EP-2178870-A1 INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG Life Sciences Ltd. (KR) 2010-04-28 EP claimed
WO-2009025478-A1 INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG LIFE SCIENCES LTD. (KR) 2009-02-26 WO claimed
US-20240374646-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME MITOIMMUNE THERAPEUTICS INC. (KR) 2024-11-14 US disclosed
US-20240269145-A1 USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS MITOIMMUNE THERAPEUTICS INC. (KR) 2024-08-15 US disclosed
US-8436038-B2 Indole and indazole compounds as an inhibitor of cellular necrosis LG LIFE SCIENCES LTD. (KR) 2013-05-07 US disclosed
US-20100197673-A1 INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS LG LIFE SCIENCES LTD (KR) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374646-A1 COMPOSITION FOR INHIBITING INFLAMMATION OR AGING OF STEM CELLS, AND METHOD FOR INHIBITING INFLAMMATION OR AGING BY USING SAME TFAM, FIS1, AIFM1 ALDH1A1 160/4885RAB9A 1879/4885NPC1 659/4885
US-20250082646-A1 OVARIAN ANTI-AGING PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP19A1, NR5A1, CYP11A1 ALDH1A1 1154/4885RAB9A 1818/4885NPC1 2853/4885
US-20250213583-A1 ANTIVIRAL PHARMACEUTICAL COMPOSITION AND USE THEREOF ZC3HAV1, ZC3HAV1L, SARS1 ALDH1A1 1088/4885RAB9A 1351/4885NPC1 22/4885
US-20100197673-A1 INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS IDO1, IDO2, NFATC1 ALDH1A1 1971/4885RAB9A 3616/4885NPC1 739/4885
US-20150038500-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OPHTHALMIC DISORDERS AQP1, EYA3, SF1 ALDH1A1 627/4885RAB9A 1582/4885NPC1 212/4885
US-20240269145-A1 USE OF INDOLE COMPOUND AS INHIBITORS OF FERROPTOSIS AIFM2, FECH, SLC40A1 ALDH1A1 547/4885RAB9A 1820/4885NPC1 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.